CAR-T药物有望进入商保;绿谷医药违规推广被罚|医药早参

每日经济新闻
Nov 03

NO.1 药明巨诺CAR-T药物有望进入商保目录  据媒体报道,药明巨诺的CAR-T细胞药物瑞基奥仑赛注射液在协商进入商保(商业健康保险)创新药目录方面进展顺利,有望纳入该目录。这是国内获批上市的第一个国产1类CAR-T,上市后的定价是129万元/针。  点评:商保目录的突破,标志着我国多层次医疗保障体系正加速构建,通过“商保+创新药”模式缓解基本医保压力,为更多高价疗法打通可及性路径。这不仅助力...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10